NCT00588536View on ClinicalTrials.gov

Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 1995

Primary Completion Date

July 31, 2008

Study Completion Date

June 30, 2009

Conditions
Langerhans Cell Histiocytosis
Interventions
DRUG

Methotrexate

MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs

DRUG

6-Thioguanine

6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.

DRUG

Leucovorin Calcium

5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00588536 - Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH | Biotech Hunter | Biotech Hunter